Immunotherapy Update: Early-Career Researcher Finds Appetite Killing Hormone Might Help Kill Cancer - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
For every $1 donated through with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.


Posted October 2, 2019

Immunotherapy Update: Early-Career Researcher Finds Appetite Killing Hormone Might Help Kill Cancer

Exciting new research supported by a SU2C Innovative Research Grant (IRG) early-career researcher has found that a natural hormone in your body that kills your appetite might also be able to kill cancer.

The research determined that leptin — a natural hormone that lets the brain know when the body is full — can be used to mobilize immune system T cells against cancers like melanoma and pancreatic cancer.

While leptin can’t be given alone as treatment, researchers developed a bioengineered virus to produce and secrete leptin that can be used to treat cancer patients. In a one-two punch against cancer, the virus itself can kill cancer cells, and the leptin made by virus infected cells can reprogram and activate the metabolism of T cells in the immune system, enabling them to attack the cancer cells. You can read the scientific paper here.

Greg M. Delgoffe, PhD, a 2016 SU2C Innovative Research Grant (IRG) recipient, is focused on immunotherapy approaches to improve and combine the use of cancer-fighting viruses with a group of drugs called immune checkpoint inhibitors to achieve a more potent immune response. To date, SU2C has supported more than $150 million in researching immunotherapy to treat cancer across its entire portfolio.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.